Memery Crystal advises on the sale of Taylor Mammon to US CBD pioneer GenCanna

Taylor Mammon, established in 2018, is a white label manufacturer and brand distributor of CBD-infused goods. The acquisition by US-based, leading producer of hemp-derived, THC-free, premium CBD and other cannabinoids, follows a 3-year relationship in which GenCanna served as Taylor Mammon’s primary source of CBD and other cannabinoids for infusion into brand products.

Taylor Mammon founders will be retained in the business to help drive the continued success of the wider group. The acquisition follows an 18-month initiative at Taylor Mammon to prepare its Novel Foods Application. The union represents a strategic acquisition by GenCanna to capitalise on an inflection point in the CBD industry by combining their expertise, infrastructure and resources and access to funds.

The Memery Crystal team was led by CEO Nick Davis alongside senior associate Karen O’Grady, solicitor Lauren Belmonte, and paralegal Priya Morzeria. Senior associate Mark Rose advised on the employment aspects of the transaction, and director Helen Abel advised on the real estate elements.

CEO Nick Davis commented: “The strategic acquisition of Taylor Mammon is another significant step forward for the industry, creating a global leader in the CBD space and narrowing the borders between the US and the UK. It was a pleasure to work with the team on this transaction and we wish them every success in their new journey.”

Cannabis is one of the world’s fastest-growing and most innovative industrial sectors. Led by CEO Nick Davis, Memery Crystal’s medicinal cannabis team are sector leaders within the UK, advising businesses on a broad range of issues. The practice includes business set-up, capital markets, mergers & acquisitions, private fundraising, licensing, and commercial contracts.